Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by VICENTE VALERO and GAIANE MARGISHVILI RAUCH.
VICENTE VALERO
Connection Strength
2.627
GAIANE MARGISHVILI RAUCH
  1. Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Sci Rep. 2024 07 12; 14(1):16073.
    View in: PubMed
    Score: 0.242
  2. Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI. Cancers (Basel). 2023 Feb 06; 15(4).
    View in: PubMed
    Score: 0.220
  3. Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. J Magn Reson Imaging. 2022 12; 56(6):1901-1909.
    View in: PubMed
    Score: 0.208
  4. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol. 2022 Apr; 149:110220.
    View in: PubMed
    Score: 0.205
  5. Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. Cancer. 2021 08 15; 127(16):2880-2887.
    View in: PubMed
    Score: 0.194
  6. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2021 Jan; 185(1):1-12.
    View in: PubMed
    Score: 0.186
  7. Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 12; 268(6):e61-e62.
    View in: PubMed
    Score: 0.164
  8. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 Oct 01; 4(10):2823-2834.
    View in: PubMed
    Score: 0.062
  9. Feasibility of breast conserving surgery alone in HER2-positive exceptional responders to neoadjuvant systemic therapy. Eur J Surg Oncol. 2024 Dec; 50(12):108613.
    View in: PubMed
    Score: 0.061
  10. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595.
    View in: PubMed
    Score: 0.060
  11. Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Front Oncol. 2023; 13:1264259.
    View in: PubMed
    Score: 0.058
  12. Patient Interest in Exploring Nonsurgical Treatment Approaches for Early-Stage Breast Cancer: A Qualitative Study. Int J Radiat Oncol Biol Phys. 2024 Feb 01; 118(2):443-454.
    View in: PubMed
    Score: 0.057
  13. Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial. JAMA Netw Open. 2023 09 05; 6(9):e2333933.
    View in: PubMed
    Score: 0.057
  14. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422.
    View in: PubMed
    Score: 0.057
  15. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13).
    View in: PubMed
    Score: 0.056
  16. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469.
    View in: PubMed
    Score: 0.056
  17. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.
    View in: PubMed
    Score: 0.056
  18. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. J Am Coll Surg. 2023 07 01; 237(1):101-108.
    View in: PubMed
    Score: 0.055
  19. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Sci Rep. 2023 01 20; 13(1):1171.
    View in: PubMed
    Score: 0.055
  20. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022 12; 23(12):1517-1524.
    View in: PubMed
    Score: 0.054
  21. Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Front Artif Intell. 2022; 5:876100.
    View in: PubMed
    Score: 0.053
  22. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 07 01; 28(13):2878-2889.
    View in: PubMed
    Score: 0.053
  23. Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer. Ultrasound Med Biol. 2022 06; 48(6):1010-1018.
    View in: PubMed
    Score: 0.052
  24. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5).
    View in: PubMed
    Score: 0.051
  25. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Acad Radiol. 2022 01; 29 Suppl 1:S35-S41.
    View in: PubMed
    Score: 0.049
  26. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. Eur J Radiol. 2020 Sep; 130:109170.
    View in: PubMed
    Score: 0.046
  27. Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2019 Oct; 26(10):3071-3079.
    View in: PubMed
    Score: 0.043
  28. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-?. Invest New Drugs. 2018 12; 36(6):1103-1109.
    View in: PubMed
    Score: 0.041
  29. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
    View in: PubMed
    Score: 0.039
  30. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.